In the fiscal year under review, consolidated net sales increased year-on-year, operating income increased, ordinary income, and profit attributable to owners of the parent decreased.
●Consolidated net sales totaled 198,380 million yen, an increase of 13,574 million yen (7.3%) year-on-year. Sales in the pharmaceuticals business underperformed, while the functional chemicals and safety systems businesses outperformed the previous fiscal year.
●Consolidated operating income totaled 21,505 million yen, an increase of 454 million yen (2.2%) year-on-year, outperforming the previous fiscal year in the pharmaceuticals and safety systems businesses, while underperforming in the functional chemicals industry.
●Consolidated ordinary income totaled 23,025 million yen, a decrease of 128 million yen (0.6%) year-on-year.
●Profit attributable to owners of parent was 14,984 million yen, a decrease of 2,196 million yen (12.8%) year-on-year, owing to recognition of an impairment loss on property, plant, and equipment.

(billions yen)	2014/03	2015/03	2016/03	2017/03	2018/03	2019/03	2020/03	2021/03	2022/03	2023/03
R&D Expenses	13.2	12.9	13.0	13.9	12.0	12.5	11.0	12.4	13.0	13.3
R&D Expenses to net sales ratio	8.2%	8.0%	8.0%	8.7%	7.1%	7.2%	6.3%	7.2%	7.0%	6.7%
Capital Investments	16.7	16.2	13.4	11.5	16.4	16.6	14.5	8.3	11.5	23.5
Depreciation and Amortization	10.4	10.7	11.2	11.3	11.6	11.9	12.3	12.8	13.5	13.7